Gyre Therapeutics, Inc. Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation
Gyre Therapeutics, Inc. (GYRE) reported Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation of $3.41 million for the 12-month period ending 2014-12-31, per its 10-K filed 2015-03-16.
Discontinued › Notes › Compensation Related Costs
us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation · last filed 2015-03-16
- Gyre Therapeutics, Inc. adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2014 was $3.41M.
- Gyre Therapeutics, Inc. adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2010 was $3.50M, a 8443.90% increase from fiscal 2009.
- Gyre Therapeutics, Inc. adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2009 was $41.00K.
| Period end | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 12 month |
|---|---|
| 2014-12-31 | $3.41M 10-K · filed 2015-03-16 |
| 2010-12-31 | $3.50M 10-K · filed 2013-03-15 |
| 2009-12-31 | $41.00K 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |